Skip to main content

William J. Bussiere, Jr.


[email protected]



Will focuses his practice on corporate and securities law matters. He has represented public and private companies in all stages of their life cycles, including company formation, venture capital and debt financing, mergers and acquisitions, capital markets transactions, and securities law compliance. He also advises companies on corporate governance matters, commercial contracts and equity compensation.

Will is also a member of the firm’s Sports & Entertainment Practice, with a focus on business contracts and charitable foundations for professional athletes. He serves on the board of directors of the Doug Flutie Jr. Foundation for Autism.

Before joining Mintz, he practiced in a boutique Massachusetts law firm, where he advised clients on corporate matters, real estate transactions, and financing and development of affordable housing, and previously practiced as a litigator in the Boston office of a Northeast law firm. Will also was a legal fellow to the general counsel of the Boston Redevelopment Authority (now known as the Boston Planning & Development Agency), where he focused on large project review, regulatory compliance, municipal asset management, and tax agreements.

While in law school, Will was Note Editor for the Boston University Law Review, and he served as a law clerk for the Boston University Office of General Counsel. He also was a legal intern for the WGBH Educational Foundation, and a judicial intern with the Massachusetts Appeals Court.


  • Boston University School of Law (JD, cum laude)
  • Providence College (BA, summa cum laude)


  • Cheetah Medical, a provider of noninvasive hemodynamic monitoring devices, in connection with its sale to Baxter International Inc. (NYSE:BAX)
  • Aura Biosciences in its $30M and $40M financings to advance the clinical development of its Ocular Melanoma treatment
  • Synlogic (NASDAQ:SYBX) in its IPO by way of a reverse merger with Mirna Therapeutics, Inc. and its $42M, $40M, $30M and $42M financings to develop “living therapeutics”
  • Endotronix in its $37M Series C and $40M Series D financings to develop a medical device system targeting heart failure management
  • NBD Nanotechnologies in Series A and Series B financings to develop repellent nanocoatings for consumer products
  • John Hancock Financial Network in its sale of Signator Investors to Advisor Group
  • Naurex in its sale to Allergan for upfront payment of $560M and additional milestones to commercialize an antidepressant therapy
  • Pedro Martinez Foundation in its U.S. relaunch and public charity conversion

Recent Insights


News & Press


Viewpoint Thumbnail

LLCs and Convertible Debt – Too Good to be True?

November 26, 2018 | Article | By Will Bussiere

Founders choosing a structure for their business are often drawn to the limited liability company, or LLC, for its overall flexibility in both taxation and governance matters. And founders seeking access to early capital, not to mention seed investors themselves, are often drawn to the convertible note as a simple, less expensive means to raise funds. But LLCs and convertible debt don’t always mix.
Read more

News & Press

Press Release Thumbnail
Mintz advised Cardurion Pharmaceuticals, Inc., a biotechnology company developing novel therapeutics to treat heart failure and other cardiovascular diseases, in a private investment of up to $300 million from Bain Capital Life Sciences and Bain Capital Private Equity that will enable the Boston-based company to expand its drug discovery programs.